日気食会報，73（2），20221） Goldstraw P, Chansky K, Crowley J, et al：The IASLC lung cancer staging project：proposals for revision of the TNM stage groupings in the forth-coming（eighth）edition of the TNM classification for lung cancer. J Thorac Oncol 11：39─51, 2016.2） Hamada C, Tanaka F, Ohta M, et al：Meta-analy-sis of postoperative adjuvant chemotherapy with tegafur-uracil in non-small-cell lung cancer. J Clin Oncol 23：4999─5006, 2005.3） Pignon JP, Tribodet H, Scagliotti GV, et al：Lung adjuvant cisplatin evaluation：a pooled analysis by the LACE collaborative group. J Clin Oncol 26：3552─3559, 2008.4） Douillard JY, Tribodet H, Aubert D, et al：Adju-vant cisplatin and vinorelbine for completely re-sected non-small cell lung cancer：subgroup anal-ysis of the lung adjuvant cisplatin evaluation. J Thorac Oncol 5：220─228, 2010.5） Borghaei H, Paz-Ares L, Horn L, et al：Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer. N Engl J Med 373：1627─1639, 2015.6） Brahmer J, Reckamp KL, Baas P, et al：Nivolum-ab versus docetaxel in advanced squamous-cell non-small-cell lung cancer. N Engl J Med 373：123─135, 2015.7） Herbst RS, Baas P, Kim DW, et al：Pembrolizum-ab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer（KEYNOTE-010）：a randomised controlled trial. Lancet 387：1540─1550, 2016.8） Reck M, Rodriguez-Abreu D, Robinson AG, et al：Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer. N Engl J Med 375：1823─1833, 2016.9） Felip E, Altorki N, Zhou C, et al：Adjuvant at-ezolizumab after adjuvant chemotherapy in re-sected stage IB-IIIA non-small-cell lung cancer（IMpower010）：a randomised, multicentre, open-label, phase 3 trial. Lancet 398：1344─1357, 2021.10） Cascone T, William WN Jr, Weissferdt A, et al：Neoadjuvant nivolumab or nivolumab plus ipilim-umab in operable non-small cell lung cancer：the phase 2 randomized NEOSTAR trial. Nat Med 27：504─514, 2021.11） Provencio M, Nadal E, Insa A, et al：Neoadjuvant chemotherapy and nivolumab in resectable non-small-cell lung cancer（NADIM）：an open-label, multicentre, single-arm, phase 2 trial. Lancet On-col 21：1413─1422, 2020.12） Lee J, Chaft J, Nicholas A, et al：Surgical and clinical outcomes with neoadjuvant atezolizumab in resectable stage IB─IIIB NSCLC：LCMC3 trial primary analysis. J Thorac Oncol 16：S59─S61, 2021.13） Shu CA, Gainor JF, Awad MM, et al：Neoadju-vant atezolizumab and chemotherapy in patients with resectable non-small-cell lung cancer：an open-label, multicentre, single-arm, phase 2 trial. Lancet Oncol 21：786─795, 2020.14） Forde PM, Spicer J, Lu S, et al：Nivolumab（NIVO）＋platinum-doublet chemotherapy（che-mo）vs chemo as neoadjuvant treatment（tx）for resectable（IB-IIIA）non-small cell lung cancer（NSCLC）in the phase 3 CheckMate 816 trial. Cancer Res 81：CT003, 2021.15） Lee CK, Man J, Lord S, et al：Clinical and molecu-lar characteristics associated with survival among patients treated with checkpoint inhibitors for ad-vanced non-small cell lung carcinoma：a system-atic review and meta-analysis. JAMA Oncol 4：210─216, 2018.16） Sugiyama E, Togashi Y, Takeuchi Y, et al：Block-ade of EGFR improves responsiveness to PD-1 blockade in EGFR-mutated non-small cell lung cancer. Sci Immunol 5：eaav3937, 2020.17） Wu YL, Tsuboi M, He J, et al：Osimertinib in re-sected EGFR-mutated non-small-cell lung cancer. N Engl J Med 383：1711─1723, 2020.18） Peters S, Spigel D, Ahn M, et al：MERMAID-1：A phase III study of adjuvant durvalumab plus chemotherapy in resected NSCLC patients with MRD＋post-surgery. J Thorac Oncol 16：S258─S259, 2021.19） Spigel DR, Peters S, Ahn MJ, et al：MERMAID-2： Phase III study of durvalumab in patients with resected, stage II-III NSCLC who become MRD＋after curative-intent therapy. J Thorac Oncol 16：S745─S746, 2021.86文 献
元のページ ../index.html#50